

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

**DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS; AND
POSSIBLE SUSPENSION OF TRADING**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) pursuant to Rules 13.09(2)(a) and 13.49(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) that there will be a delay in publication of the Company’s annual results for the year ended 31 December 2024 (the “**2024 Annual Results**”) as the Company is still in the process of collecting and collating the necessary information and documents mainly in relation to three separate investments totalling at RMB91.5 million as required by the auditor of the Company (the “**Auditor**”) to complete the auditing process, and hence additional time is required for the Company to prepare the 2024 Annual Results. The Company is working closely with the Auditor to provide the required information and documents to complete the audit procedures as soon as possible. However, the expected date of the publication of the 2024 Annual Results will need to be further discussed and determined with the Auditor and will be announced as and when appropriate.

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the 2024 Annual Results not later than three months after the end of the financial year (i.e. on or before 31 March 2025). In light of the aforementioned circumstances, the Company is unable to publish the 2024 Annual Results on or before 31 March 2025, as required by the Listing Rules.

Pursuant to Rule 13.49(3) of the Listing Rules, if the Company is unable to publish the 2024 Annual Results within the prescribed timeframe, it must announce its results prepared based on the financial results which have yet to be agreed upon with the auditors (so far as such information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the

Company to publish the unaudited management accounts of the Group for the year ended 31 December 2024 at this stage as they may not accurately reflect the financial performance and/or position of the Group and the publication of the unaudited management accounts could cause confusion and may be misleading to the Shareholders and potential investors of the Company.

POSTPONEMENT OF BOARD MEETING

As disclosed in the announcement of the Company dated 17 March 2025, the meeting of the Board (the “**Board Meeting**”) was originally scheduled to be held on 31 March 2025 to consider and approve the 2024 Annual Results and its publication. Due to the aforesaid delay in the publication of the 2024 Annual Results, the Board Meeting will be postponed. The Company will make further announcement(s) in due course to inform the Shareholders of the latest information, if any, and the date of Board Meeting.

POSSIBLE SUSPENSION OF TRADING

Pursuant to Rule 13.50 of the Listing Rules, if the issuer fails to publish periodic financial information in accordance with the Listing Rules, the Stock Exchange will normally request suspension of trading in the issuer’s securities and the suspension will normally continue until the issuer publishes an announcement containing the requisite financial information.

Although the Company is working closely with the Auditors to complete the audit procedures as soon as possible, since the Company is unable to publish the 2024 Annual Results on or before 31 March 2025, the Company will apply for a suspension of trading in its shares on the Stock Exchange with effect from 9:00 a.m. on 1 April 2025 pending publication of the 2024 Annual Results.

Further announcement will be made by the Company as and when appropriate in accordance with the Listing Rules.

The Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By Order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
Dr. Tang Li
Chairperson and Executive Director

Beijing, the PRC, 31 March 2025

As at the date of this announcement, the Board of the Company comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Mr. Zhu Pai as non-executive Directors; and (iii) Dr. Meng Songdong and Mr. Ran Dong as independent non-executive Directors.